verapamil al 80 mg filmtabletta
aliud pharma gmbh - verapamil -
fotivda
recordati netherlands b.v. - tivozanib - karcinóma, vese sejt - daganatellenes szerek - fotivda a fejlett vesesejtes karcinóma (rcc) felnőtt betegek első vonalbeli kezelésében javallott, és azoknál a felnőtt betegeknél, akik vegfr és az mtor útvonal gátló naiv következő progresszió cytokin terápia egy előzetes kezelés után speciális rcc. kezelés előrehaladott vesesejtes karcinóma.
lorviqua
pfizer europe ma eeig - lorlatinib - karcinóma, nem kissejtes tüdő - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - daganatellenes szerek - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.
eleber 60 mg koncentrátum és oldószer oldatos infúzióhoz
zentiva, k.s. (csehország) - cabazitaxel -
lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - daganatellenes szerek - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
zokinvy
eigerbio europe limited - lonafarnib - progeria; laminopathies - egyéb táplálkozási traktus pedig anyagcsere termékek, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.
crestor 10 mg filmtabletta
astrazeneca kft. - rosuvastatin -
crestor 20 mg filmtabletta
astrazeneca kft. - rosuvastatin -
crestor 40 mg filmtabletta
astrazeneca kft. - rosuvastatin -